Frost Gamma Amends BioCardia Ownership Disclosure

TL;DR

Frost Gamma Investments Trust just filed an amendment to their BioCardia ownership, signaling a change in their stake or intentions.

AI Summary

Frost Gamma Investments Trust, along with group member Phillip Frost, M.D., filed an Amendment No. 5 to their Schedule 13D (SC 13D/A) regarding BioCardia, Inc. on February 27, 2024. This filing updates previous disclosures concerning their beneficial ownership of BioCardia's Common Stock, par value $.001. The amendment indicates a change in the information previously reported by the reporting persons.

Why It Matters

A Schedule 13D/A filing indicates a material change in beneficial ownership or investment intent by a significant shareholder. This update provides transparency to the market regarding the holdings and potential influence of Frost Gamma Investments Trust in BioCardia, Inc.

Risk Assessment

Risk Level: low — This is an amendment to a standard ownership disclosure, which typically carries low direct risk unless the underlying change is hostile or highly significant, which is not indicated here.

Key Numbers

• Amendment No. 5 — Filing Amendment (Indicates multiple prior filings for this ownership)

Key Players & Entities

• BioCardia, Inc. (company) — Subject Company
• Frost Gamma Investments Trust (company) — Filing Party
• Phillip Frost, M.D. (person) — Group Member
• $.001 (dollar_amount) — Par value of Common Stock

FAQ

Key Financial Figures

• $0.40 — multiple trades at prices ranging from $0.40 to $0.51 in the open market as describe
• $0.51 — trades at prices ranging from $0.40 to $0.51 in the open market as described in the
• $0.4611 — Price Range February 7, 2024 20,000 $0.4611 – $0.4301 February 8, 2024 64,
• $0.4301 — bruary 7, 2024 20,000 $0.4611 – $0.4301 February 8, 2024 64,846 $0.4338 &nd
• $0.4338 — sh; $0.4301 February 8, 2024 64,846 $0.4338 – $0.4000 February 9, 2024 20,
• $0.4000 — bruary 8, 2024 64,846 $0.4338 – $0.4000 February 9, 2024 20,000 $0.4200 &nd
• $0.4200 — sh; $0.4000 February 9, 2024 20,000 $0.4200 – $0.4000 February 12, 2024 20
• $0.4098 — h; $0.4000 February 12, 2024 20,000 $0.4098 – $0.4497 February 13, 2024 20
• $0.4497 — ruary 12, 2024 20,000 $0.4098 – $0.4497 February 13, 2024 20,000 $0.4070 &n
• $0.4070 — h; $0.4497 February 13, 2024 20,000 $0.4070 – $0.4434 February 14, 2024 20
• $0.4434 — ruary 13, 2024 20,000 $0.4070 – $0.4434 February 14, 2024 20,000 $0.4150 &n
• $0.4150 — h; $0.4434 February 14, 2024 20,000 $0.4150 – $0.4430 February 15, 2024 20
• $0.4430 — ruary 14, 2024 20,000 $0.4150 – $0.4430 February 15, 2024 20,000 $0.4200 &n
• $0.4700 — ruary 15, 2024 20,000 $0.4200 – $0.4700 February 16, 2024 20,000 $0.4300 &n
• $0.4300 — h; $0.4700 February 16, 2024 20,000 $0.4300 – $0.4460 February 20, 2024 20

Filing Documents

• tm247389d1_sc13da.htm (SC 13D/A) — 58KB
• tm247389d1_ex1.htm (EX-99.1) — 4KB
• 0001104659-24-028261.txt ( ) — 65KB

is hereby amended and restated to read as follows

Item 3 is hereby amended and restated to read as follows. The information set forth or incorporated under the heading “Explanatory Note” and in Items 4 and 5 is incorporated by reference in its entirety into this Item 3. The source of funds used by Dr. Frost and FGIT for each of its acquisitions of securities of the Issuer was working capital of FGIT. ITEM 4. PURPOSE OF TRANSACTION No change. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER Items 5(a)-(b), (d) are hereby amended and restated to read as follows: (a)(b), (d) FGIT holds 1,571,179 shares of Common Stock, or approximately 6.1% of the Issuer’s issued and outstanding shares, based on 25,913,503 shares of Common Stock outstanding as of February 14, 2024, as reported by the Issuer on Form S-3 filed with the SEC on February 14, 2024. On February 7, 2024 to February 27, 2024, Dr. Frost disposed of an aggregate of 324,846 shares of Common Stock in multiple trades at prices ranging from $0.40 to $0.51 in the open market as described in the table below. Date Number of Shares Disposed Price Range February 7, 2024 20,000 $0.4611 – $0.4301 February 8, 2024 64,846 $0.4338 – $0.4000 February 9, 2024 20,000 $0.4200 – $0.4000 February 12, 2024 20,000 $0.4098 – $0.4497 February 13, 2024 20,000 $0.4070 – $0.4434 February 14, 2024 20,000 $0.4150 – $0.4430 February 15, 2024 20,000 $0.4200 – $0.4700 February 16, 2024 20,000 $0.4300 – $0.4460 February 20, 2024 20,000 $0.4400 – $0.4600 February 21, 2024 20,000 $0.4000 – $0.4700 February 22, 2024 20,000 $0.4100 – $0.4400 February 23, 2024 20,000 $0.4200 – $0.4500 February 26, 2024 20,000 $0.4400 – $0.4700 February 27, 2024 20,000 $0.4600 – $0.5100 Dr. Frost is the sole trustee of FGIT. On June 6, 2019, the Issuer effected a 1-9 reverse stock split of its common stock (the "Reverse Stock Split"). The

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct. Date: February 27, 2024 Dr. Phillip Frost By: /s/ Phillip Frost, M.D. Frost Gamma Investments Trust By: /s/ Phillip Frost, M.D. Phillip Frost, M.D. Trustee

View Full Filing

View this SC 13D/A filing on SEC EDGAR